Syndax Pharmaceuticals, Inc. (SNDX)
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced
Syndax has transitioned into a two-product commercial oncology company with growing revenue and strong cash reserves. Revuforj and Niktimvo drive SNDX's revenue, with Q1 2026 net sales exceeding $100M and significant expansion potential in AML and chronic GVHD. Revuforj's broad FDA approval and post-transplant maintenance potential, alongside Niktimvo's unique mechanism, underpin a multi-billion dollar franchise opportunity.
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.98 per share a year ago.
Syndax Pharma: Two Drug Launches Fuel Transformational Growth
Syndax Pharma delivered robust Q4 2025 results, with sales of $68.7 million (+794.5% YoY), driven by Revuforj and Niktimvo. Revuforj's rapid commercialization and label expansion position SNDX to access a $5 billion+ AML market, with 1L Phase 3 trials as a major catalyst. Niktimvo's strong launch in GVHD and operational leverage support increasing collaboration revenue, with potential market doubling via frontline studies.
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
Sphera Funds added 374,847 shares of Syndax Pharmaceuticals in the fourth quarter. The quarter-end position value rose by $10.06 million, reflecting both trading and price movement.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $1.1 per share a year ago.
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026
Syndax Pharmaceuticals (SNDX) demonstrates strong commercial momentum with Revuforj and Niktimvo, driving notable revenue growth post-FDA approvals. Revuforj's 4Q25 net revenue surged 38% QoQ to $44M, while Niktimvo delivered $56M, underscoring robust adoption in underserved patient populations. SNDX maintains a solid $394M cash position, supporting ongoing clinical trials and pipeline expansion, though competition from Komzifti introduces new risks.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
